Exhibit 4.2


 


AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT


 


THIS
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of this 29th
day of March, 2021, by and among Entrada Therapeutics, Inc. (f/k/a CycloPorters, Inc.), a Delaware corporation (the “Company”),
each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”
and each of the entities listed on Schedule B hereto, each of which is referred to in this Agreement as a “Licensor Stockholder.”


 


RECITALS


 


WHEREAS,
certain of the Investors (the “Existing Investors”) and the Licensor Stockholder are parties to that certain Investors’
Rights Agreement, dated as of December 14, 2018, by and among the Company and such Existing Investors (the “Prior Agreement”);


 


WHEREAS,
pursuant to Section 6.6 of the Prior Agreement, the Prior Agreement may be amended by the written consent of the Company and the
holders of at least 54% of the then-outstanding shares of Preferred Stock (as defined below);


 


WHEREAS,
the undersigned Existing Investors collectively hold at least 54% of the shares of Preferred Stock currently outstanding, and the Company
and the Existing Investors desire to amend and restate the Prior Agreement in its entirety and to accept the rights and obligations provided
by this Agreement in lieu of the rights and obligations provided by the Prior Agreement; and


 


WHEREAS,
concurrently with the execution of this Agreement, the Company and certain of the Investors are entering into a Series B Preferred
Stock Purchase Agreement (as amended or restated from time to time, the “Purchase Agreement”), and such Investors’
obligations to purchase shares of Series B Preferred Stock (as defined below) are conditioned upon the execution and delivery of
this Agreement.


 


NOW,
THEREFORE, the Company, the Existing Investors hereby agree that the Prior Agreement shall be amended and restated and shall
be of no further force or effect and shall be superseded and replaced in its entirety by this Agreement, and the parties to this Agreement
further agree as follows:


 


1.            Definitions.
For purposes of this Agreement:


 


1.1            “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person,
or any venture capital or other investment fund or registered investment company now or hereafter existing that is controlled by one or
more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such
Person. Anything to the contrary in this paragraph notwithstanding, (i) neither Chugai Pharmaceutical Co., Ltd, a Japanese corporation
(“Chugai”) and/or its subsidiaries (if any) nor Foundation Medicine, Inc., a Delaware corporation (“FMI”)
and/or its subsidiaries, if any, shall be deemed as Affiliates of Roche Finance Ltd unless Roche Finance Ltd provides written notice of
its desire to include Chugai, FMI and/or their respective subsidiaries (as applicable) as Affiliate(s) of Roche Finance Ltd.


 



    	 	 1	 



     


    




 


1.2             “Board”
or “Board of Directors” means the board of directors of the Company.


 


1.3             “Certificate
of Incorporation” means the Company’s Third Amended and Restated Certificate of Incorporation, as amended and/or restated
from time to time.


 


1.4             “Common
Stock” means shares of the Company’s common stock, par value $0.0001 per share.


 


1.5             “Damages”
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the
Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement
of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein
not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the
Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange
Act, or any state securities law.


 


1.6             “Derivative
Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly),
Common Stock, including options and warrants.


 


1.7             “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


1.8             “Excluded
Registration” means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be
included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.


 


1.9             “Form S-1”
means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently
adopted by the SEC.


 


1.10           “Form S-3”
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently
adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company
with the SEC.


 



    	 	 2	 



     


    




 


1.11           “GAAP”
means generally accepted accounting principles in the United States as in effect from time to time.


 


1.12           “Holder”
means any holder of Registrable Securities who is a party to this Agreement.


 


1.13           “Immediate
Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized
domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive
relationships, of a natural person referred to herein.


 


1.14           “Initiating
Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.


 


1.15           “IPO”
means the Company’s first underwritten public offering of its Common Stock under the Securities Act.


 


1.16           “New
Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options,
or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.


 


1.17           “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.


 


1.18           “Preferred
Stock” means, collectively, shares of the Company’s Series Seed Preferred Stock, the Series A Preferred Stock
and the Series B Preferred Stock.


 


1.19           “Preferred
Director” means any director of the Company that the holders of record of the Series A Preferred Stock or Series B
Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation.


 


1.20           “Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common
Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the
Company, acquired by the Investors on or after the date hereof; (iii) any Common Stock held by the Licensor Stockholders; and (iv) any
Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i), (ii) and
(iii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable
rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2
any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement.


 


1.21           “Registrable
Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock
that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable
and/or convertible securities that are Registrable Securities.


 



    	 	 3	 



     


    







 


1.22           “Restricted
Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(b) hereof.


 


1.23           “Requisite
Majority” means the holders of a majority of the then-outstanding shares of (i) Series A Preferred Stock and (ii) Series B
Preferred Stock, each voting as a separate series.


 


1.24           “Rights
Stockholder” means (i) any Investor that holds any shares of Common Stock issued or issuable upon conversion of the Preferred
Stock and (ii) any Licensor Stockholder that holds any shares of Common Stock.


 


1.25           “SEC”
means the Securities and Exchange Commission.


 


1.26           “SEC
Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.


 


1.27           “SEC
Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.


 


1.28           “Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


1.29           “Selling
Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in Section 2.6.


 


1.30           “Series A
Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share.


 


1.31           “Series B
Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share.


 


1.32           “Series Seed
Preferred Stock” means shares of the Company’s Series Seed Preferred Stock, par value $0.0001 per share.


 


1.33           “Wellington
Investor” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P.


 






    	 	 4	 



     


    

 


2.            Registration
Rights. The Company covenants and agrees as follows:


 


2.1            Demand
Registration


 


(a)            Form S-1
Demand. If, at any time after the earlier of (i) three (3) years after the date of this Agreement or (ii) one hundred
eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a
majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to the
Registrable Securities having an anticipated aggregate offering price, net of Selling Expenses, that would exceed $15 million, then the
Company shall: (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”)
to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the
date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20)
days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3.


 


(b)            Form S-3
Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders
of at least fifteen percent (15%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement
with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses,
of at least $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand
Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45)
days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities
Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given
by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations
of Sections 2.1(c) and 2.3.


 


(c)            Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate
signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental
to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such
registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure
of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company
unable to comply with requirements under the Securities Act or the Exchange Act, then the Company shall have the right to defer taking
action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however,
that the Company may not invoke this right more than twice in any twelve (12) month period; and provided further that the Company
shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period
other than an Excluded Registration.


 


(d)            The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a) (i) during
the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that
is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the
Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose
of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b).
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during
the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that
is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing
in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has
effected two registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date
of such request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until
such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration
statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected”
for purposes of this Section 2.1(d); provided, that if such withdrawal is during a period the Company has deferred
taking action pursuant to Section 2.1(c), then the Initiating Holders may withdraw their request for registration and such
registration will not be counted as “effected” for purposes of this Section 2.1(d).


 



    	 	 5	 



     


    







 


2.2            Company
Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders
other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely
for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.
Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to
the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested
to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable
Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company
in accordance with Section 2.6.


 


2.3            Underwriting
Requirements.


 


(a)            If,
pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the
Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably
acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion
of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their
securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting
agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3,
if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number
of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among
such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable
Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided,
however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced
unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with
the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred
(100) shares.


 



    	 	 6	 



     


    




 


(b)            In
connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2,
the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders
seeking to sell Registrable Securities in such offering accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of
the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included
in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion
determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number
of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not
jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be
registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in
such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred
(100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering
be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering,
or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of
securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the
underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes
of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder,
or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the
benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with
respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included
in such “selling Holder,” as defined in this sentence.


 


(c)            For
purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the
underwriter’s cutback provisions in Section 2.3(a), fewer than the total number of Registrable Securities that Holders
have requested to be included in such registration statement are actually included.


 



    	 	 7	 



     


    




 


2.4            Obligations
of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible:


 


(a)             prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts
to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier,
until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such
one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of
an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in
the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis,
subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to one hundred eighty
(180) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;


 


(b)             prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such
registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered
by such registration statement;


 


(c)             furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;


 


(d)             use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall
not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless
the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;


 


(e)             in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter(s) of such offering;


 


(f)             use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;


 



    	 	 8	 



     


    

 


(g)            provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;


 


(h)            promptly
make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration
statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees,
and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate
due diligence in connection therewith;


 


(i)             notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed; and


 


(j)             after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.


 


In addition, the Company shall ensure that, at
all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have
become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1
of the Exchange Act.


 


2.5            Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2
with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to
effect the registration of such Holder’s Registrable Securities.


 


2.6            Expenses
of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees
and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $75,000, of one counsel for the
selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however,
that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1
if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be
registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that
were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities to be registered agree
to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided
further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business,
or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit
their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable
Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number
of Registrable Securities registered on their behalf.


 






    	 	 9	 



     


    

 


2.7            Delay
of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of
this Section 2.


 


2.8            Indemnification.
If any Registrable Securities are included in a registration statement under this Section 2:


 


(a)            To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors,
and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or
the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages
to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection
with such registration.


 


(b)            To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any
other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against
any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon
and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not
apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by
any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.


 



    	 	 10	 



     


    

 


(c)            Promptly
after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is
to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof.
The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory
to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying
party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices
the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it
of any liability that it may have to any indemnified party otherwise than under this Section 2.8.


 


(d)            To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8
provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party
hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute
to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such
proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any
other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission
of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative
intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person
who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability
pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b),
exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of
willful misconduct or fraud by such Holder.


 



    	 	 11	 



     


    

 


(e)            Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of
the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a
registration under this Section 2, and otherwise shall survive the termination of this Agreement.


 


2.9            Reports
Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation
of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company shall:


 


(a)            make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO;


 


(b)            use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and


 


(c)            furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written
statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days
after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at
any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may
be resold pursuant to Form S-3 (at any time after the Company so qualifies) and (ii) such other information as may be reasonably
requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration
(at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at
any time after the Company so qualifies to use such form).


 


2.10            Limitations
on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent
of the Holders of the Requisite Majority, enter into any agreement with any holder or prospective holder of any securities of
the Company that would (i) allow such holder or prospective holder to include such securities in any registration unless, under
the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent
that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included, or (ii) allow
such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder;
provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party
to this Agreement in accordance with Section 6.9.


 



    	 	 12	 



     


    

 


2.11            “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter,
during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company
and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be requested by the
Company or an underwriter and required to accommodate regulatory restrictions on (1) the publication or other distribution of research
reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in applicable FINRA
rules, or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract
to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose
of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or
indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such
securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock
or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall
not apply to transactions (including, without limitation, any swap, hedge or similar agreement or arrangement), in each case, relating
to securities acquired in the IPO or securities acquired in open market or other transactions from and after the IPO or that otherwise
that do not involve or relate to shares of Common Stock owned by a Holder prior to the IPO, shall not apply to the sale of any shares
to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit
of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall
be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company obtains a similar
agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after
giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration
are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the
provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested
by the underwriters in connection with such registration that are consistent with this Section 2.11 that are necessary to
give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company
or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based on the number of shares
subject to such agreements.


 


2.12            Restrictions
on Transfer.


 


(a)            The
Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize
and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions
specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder
to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding
the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the
IPO, SEC Rule 144, in each case, to be bound by the terms of this Agreement.


 



    	 	 13	 



     


    

 


(b)            Each
certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any
other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization,
merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated
with a legend substantially in the following form:


 


THE SECURITIES REPRESENTED HEREBY HAVE
BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD,
PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF SAID ACT.


 


THE SECURITIES REPRESENTED HEREBY MAY BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH
THE SECRETARY OF THE COMPANY.


 


The Holders consent to the Company
making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the
restrictions on transfer set forth in this Section 2.12.


 


(c)            The
holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s
intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale,
pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense
by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company,
addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a
 “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any
other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted
Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be
entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the
Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance
with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such
Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12.
Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with,
except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b),
except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel
for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.


 



    	 	 14	 



     


    

 


2.13       Termination
of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of:


 


(a)         the
closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation;


 


(b)         such
time after consummation of the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale
of all of such Holder’s shares without limitation during a three (3)-month period without registration; and


 


(c)         the
fifth (5th) anniversary of the IPO.


 


3.            Information
and Observer Rights.


 


3.1         Delivery
of Financial Statements. The Company shall deliver to each Rights Stockholder, upon request of such Rights Stockholder (provided
that the Board has not determined that such Rights Stockholder is a competitor, and provided further, that a Rights Stockholder
shall not be deemed a competitor of the Company solely due to its or its Affiliates’ ownership of any equity or membership interest
of any entity or due to the service of any partner or employee of such Rights Stockholder or its Affiliates on the board of directors
or other governing body of any company of which such Rights Stockholder or its Affiliates holds any equity or membership interest):


 


(a)          as
soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company (i) a balance sheet as of
the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts
as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Section 3.1(e))
for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications
of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements
audited and certified by independent public accountants of nationally recognized standing selected by the Board beginning with fiscal
year 2021;


 


(b)          as
soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal
year of the Company, unaudited statements of income and cash flows for such fiscal quarter, an unaudited balance sheet, and a statement
of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements
may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance
with GAAP);


 



    	 	 15	 



     


    

 


(c)             as
soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the Company, a
statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares
of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities
convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of
issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Rights
Stockholders to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or
chief executive officer of the Company as being true, complete, and correct;


 


(d)             as
soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement and statement of
cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that
such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that
may be required in accordance with GAAP);


 


(e)             as
soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal
year (collectively, the “Budget”), approved by the Board and prepared on a monthly basis, including balance sheets,
income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared
by the Company; and


 


(f)             such
other information relating to the financial condition, business, prospects, or corporate affairs of the Company as such Rights Stockholder
may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1
to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel.


 


If, for any period, the Company
has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements
delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such
consolidated subsidiaries.


 


Notwithstanding anything else
in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1
during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related
offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the
Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.


 



    	 	 16	 



     


    

 


3.2            Inspection.
The Company shall permit each Rights Stockholder or an accountant of a Rights Stockholder (provided that the Board has not determined
that such Rights Stockholder is a competitor, and provided further, that a Rights Stockholder shall not be deemed a competitor
of the Company solely due to its or its Affiliates’ ownership of any equity or membership interest of any entity or due to the
service of any partner or employee of such Rights Stockholder or its Affiliates on the board of directors or other governing body of
any company of which such Rights Stockholder or its Affiliates holds any equity or membership interest) at such Rights Stockholder’s
expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s
affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the
Rights Stockholder; provided, however, that the Company shall not be obligated pursuant to this Section 3.2
to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely
affect the attorney-client privilege between the Company and its counsel.


 


3.3            Observer
Rights.


 


(a)            As
long as 5AM Ventures V, L.P., together with its Affiliates (“5AM Ventures”), holds at least 1,000,000 shares of Common
Stock issued or issuable upon conversion of the Preferred Stock, the Company shall invite a representative of 5AM Ventures to attend all
meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes,
consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided (in
a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and provided further, that the Company
reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such
information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or
result in disclosure of trade secrets or a conflict of interest, or if 5AM Ventures or its representative is a competitor of the Company.


 


(b)            As
long as MRL Ventures Fund, LLC, together with its Affiliates (“MRL Ventures”), holds at least 1,000,000 shares of Common
Stock issued or issuable upon conversion of the Preferred Stock, the Company shall invite a representative of MRL Ventures to attend all
meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes,
consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that such representative shall agree to hold in confidence and trust with respect to all information so provided (in
a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and provided further, that the Company
reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such
information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or
result in disclosure of trade secrets or a conflict of interest.


 



    	 	 17	 



     


    




 


(c)            As
long as Baker Brothers Life Sciences, L.P. and 667, L.P., together with their Affiliates (collectively, the “BBI Funds”),
hold at least 50% of the Series B Preferred Stock (or other securities which the Series B Preferred Stock may be exchanged or
converted into) they purchased pursuant to the Purchase Agreement, the Company shall invite a representative designated by the BBI Funds
to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all
notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided
to such directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to all information
so provided (in a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and provided further,
that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof
if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and
its counsel or result in disclosure of trade secrets or a conflict of interest, or if the BBI Funds or their representative are a competitor
of the Company.


 


(d)            As
long as Greenspring Early Stage I, L.P., together with its Affiliates (“Greenspring Associates”), holds at least 1,000,000
shares of Common Stock issued or issuable upon conversion of the Series B Preferred Stock, the Company shall invite a representative
of Greenspring Associates to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative
copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner
as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust with respect to
all information so provided (in a manner consistent with the confidentiality obligations of a director of a Delaware corporation); and
provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting
or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between
the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if Greenspring Associates or its representative
is a competitor of the Company.


 


3.4            Termination
of Information and Observer Rights. The covenants set forth in Section 3.1, Section 3.2 and Section 3.3 shall terminate
and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes
subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing
of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation (other than a sale of all or substantially
all of the Company’s assets), whichever event occurs first.


 



    	 	 18	 



     


    

 


3.5            Confidentiality.
Each Investor and Licensor Stockholder agrees that such Investor or Licensor Stockholder will keep confidential and will not disclose
or divulge for any purpose any confidential information obtained from the Company (including notice of the Company’s intention
to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other
than as a result of a breach of this Section 3.4 by such Investor or Licensor Stockholder), (b) is or has been independently
developed or conceived by the Investor or Licensor Stockholder without use of the Company’s confidential information, or (c) is
or has been made known or disclosed to the Investor or Licensor Stockholder by a third party without a breach of any obligation of confidentiality
such third party may have to the Company; provided, however, that an Investor or Licensor Stockholder may disclose confidential information
(i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection
with monitoring its investment in the Company; (ii) to any prospective purchaser of any capital stock of the Company from such Investor
or Licensor Stockholder, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to
any existing or prospective Affiliate, partner, partner of the Investor’s partnership, subsequent partnerships under common investment
management with Investor, member, stockholder, or wholly owned subsidiary of such Investor or Licensor Stockholder in the ordinary course
of business, provided that such Investor or Licensor Stockholder informs such Person that such information is confidential and directs
such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the
Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.


 


4.            Rights
to Future Stock Issuances.


 


4.1            Right
of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company
proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Rights Stockholder. Each such
Rights Stockholder shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate,
among (i) itself, (ii) its Affiliates, and (iii) its beneficial interest holders, such as limited partners, members or
any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange
Act, of such Rights Stockholder (“Investor Beneficial Owners”); provided that each such Affiliate or Investor
Beneficial Owner (x) is not a competitor, or is otherwise permitted, as determined by the Board, provided, that an Affiliate or
Investor Beneficial Owner shall not be deemed a competitor of the Company solely due to such Affiliate’s or Investor Beneficial
Owner’s ownership of any equity or membership interest of any entity or due to the service of any partner or employee of such Affiliate
or Investor Beneficial Owner on the board of directors or other governing body of any company of which such Affiliate or Investor Beneficial
Owner holds any equity or membership interest, (y) agrees to enter into this Agreement and each of the Voting Agreement and Right
of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as
an “Investor” under each such agreement (provided that any competitor shall not be entitled to any rights as
a Rights Stockholder under Sections 3.1, 3.2 and 4.1 hereof), and (z) agrees to purchase at least such number
of New Securities as are allocable hereunder to the Investor holding the fewest number of shares of Preferred Stock and any other Derivative
Securities.


 


(a)            The
Company shall give notice (the “Offer Notice”) to each such Rights Stockholder, stating (i) its bona fide intention
to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon
which it proposes to offer such New Securities.


 






    	 	 19	 



     


    

 


(b)             By
notification to the Company within twenty (20) days after the Offer Notice is given, each Rights Stockholder may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals
the proportion that the Common Stock then held by such Rights Stockholder (including all shares of Common Stock then issuable (directly
or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by
such holder) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable,
of all Preferred Stock and other Derivative Securities) At the expiration of such twenty (20) day period, the Company shall promptly notify
each Rights Stockholder that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Rights Stockholder”)
of any other Rights Stockholder’s failure to do likewise. During the ten (10) day period commencing after the Company has given
such notice, each Fully Exercising Rights Stockholder may, by giving notice to the Company, elect to purchase or acquire, in addition
to the number of shares specified above, up to that portion of the New Securities for which Rights Stockholders were entitled to subscribe
but that were not subscribed for by the Rights Stockholders which is equal to the proportion that the Common Stock issued and held, or
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities
then held, by such Fully Exercising Rights Stockholder bears to the Common Stock issued and held, or issuable (directly or indirectly)
upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising
Rights Stockholders who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall
occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant
to Section 4.1(c).


 


(c)             If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer
and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no
more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale
of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the
right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Rights
Stockholders in accordance with this Section 4.1.


 


(d)             The
right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Certificate
of Incorporation); (ii) shares of Common Stock issued in the IPO; or (iii) the issuance of shares of Series B Preferred
Stock pursuant to the Purchase Agreement.


 






    	 	 20	 



     


    

 


(e)            In
the event that the rights of a Rights Stockholder to purchase New Securities under this Section 4.1 are waived with respect
to a particular offering of New Securities without such Rights Stockholder’s prior written consent (a “Waived Investor”)
and any Rights Stockholder that participated in waiving such rights (a “Waiving Investor”) actually purchases New Securities
in such offering, then the Company shall grant, and hereby grants, each Waived Investor the right to purchase, in a subsequent closing
of such issuance on the same terms and conditions as such Waiving Investor (but excluding any attendant right to designate a member of
or observer to the Company’s Board of Directors), the same percentage of its full pro rata share of such New Securities as the highest
percentage of any such purchasing Waiving Investor, provided that such subsequent closing is consummated prior to forty-five (45)
days after the closing of such offering of New Securities.


 


(f)            Notwithstanding
any provision hereof to the contrary, in lieu of complying with the provisions of this Section 4.1 the Company may elect to
give notice to the Rights Stockholders within thirty (30) days after the issuance of New Securities. Such notice shall describe the type,
price, and terms of the New Securities. Each Rights Stockholder shall have twenty (20) days from the date notice is given to elect to
purchase up to the number of New Securities that would, if purchased by such Rights Stockholder, maintain such Rights Stockholder’s
percentage-ownership position, calculated as set forth in Section 4.1(b) before giving effect to the issuance of such
New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Rights Stockholders.


 


4.2            Termination.
The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the
consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or
15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event (other than a sale of all or substantially
all of the Company’s assets), whichever occurs first.


 


5.            Additional
Covenants.


 


5.1            Insurance.
The Company shall maintain, from financially sound and reputable insurers Directors and Officers liability in an amount and on terms
and conditions satisfactory to the Board, and will use commercially reasonable efforts to cause such insurance policies to be maintained
until such time as the Board determines that such insurance should be discontinued.


 


5.2            Employee
Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or
any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement in a
form reasonably acceptable to the Board, including the Requisite Directors (as defined below).


 






    	 	 21	 



     


    

 


5.3           Employee
Stock. Unless otherwise approved by the Board, including a majority of the Preferred Directors then in office (the “Requisite
Directors”), all employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares
of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable,
providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting
following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over
the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Section 2.11.
Without the prior approval by the Board, including the Requisite Directors, the Company shall not amend, modify, terminate, waive or
otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or service
provider if such amendment would cause it to be inconsistent with this Section 5.3. In addition, unless otherwise approved
by the Board, including the Requisite Directors, the Company shall retain (and not waive) a “right of first refusal” on employee
transfers until the IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of
restricted stock.


 


5.4           Matters
Requiring Board Approval. So long as the holders of Preferred Stock are entitled to elect any Preferred Directors, the Company hereby
covenants and agrees with each of the Investors that it shall not, nor shall it permit any of its subsidiaries to, without approval of
the Board, which approval must include the affirmative vote of the Requisite Directors:


 


(a)             make
any investment inconsistent with any investment policy approved by the Board;


 


(b)             otherwise
enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as
defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person (provided that any interested director may not be a
consenting director);


 


(c)             hire,
terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to executive officers;


 


(d)             sell,
assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course
of business; or


 


(e)             enter
into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money
or assets greater than $100,000.


 


5.5             Board
Matters. Unless otherwise determined by the vote of a majority of the directors then in office, including the Requisite Directors,
the Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors
for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending
meetings of the Board. Each non-employee director shall be entitled in such person’s discretion to be a member of any committee
of the Board.


 


5.6             Successor
Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not
the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall
be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of
members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be.


 






    	 	 22	 



     


    

 


5.7            Indemnification
Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board by the Investors
(each an “Investor Director” and collectively, the “Investor Directors”) may have certain rights
to indemnification, advancement of expenses and/or insurance provided by one (1) or more of the Investors and certain of their Affiliates
(collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first
resort (i.e., its obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance
expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that
it shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount
of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent
legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between
the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors,
and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor
Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement
or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director
has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution
and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against
the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Section 5.7
and shall have the right, power and authority to enforce the provisions of this Section 5.7 as though they were a party to
this Agreement.


 


5.8            Right
to Conduct Activities. The Company hereby agrees and acknowledges that each of the Investors (and each of their Affiliates) is a
professional investment organization, and as such reviews the business plans and related proprietary information of many enterprises,
some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to
be conducted). The Company hereby agrees that, to the extent permitted under applicable law, each of the Investors (and each of their
Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by an Investor (or
its Affiliates) in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative
of such Investor (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the
board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company;
provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized
disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of
the Company from any liability associated with his or her fiduciary duties to the Company.


 






    	 	 23	 



     


    

 


5.9            Restrictions
on Publicity. The Company shall not, without the express prior approval of an Investor (which may be given or withheld in such Investors’
sole discretion) issue any press release, advertisement or announcement (in whatever form) disclosing that such Investor has invested
in the Company, or make any other disclosure regarding such Investor or its Affiliates. Further, the Company shall not use the name or
logo of an Investor or its Affiliates (including portions of such Investor’s name or any derivation or abbreviation thereof), or
refer to an Investor or its Affiliates, directly or indirectly, in connection with such Investor’s or its Affiliates’ relationship,
agreements or arrangements with the Company in any advertisement, press release, professional or trade publication, or in any other manner,
except (a) as may be required by law, rule, or regulation (including, without limitation, any rule or regulation promulgated
by the SEC or any other regulatory authority), (b) on a confidential basis to potential financing sources including lenders, investors,
investment bankers or acquirors, (c) on a confidential basis to the Company’s lawyers, contractors, accountants and other
advisors who have a need to have access and knowledge of such information or (d) with such Investor’s prior written consent,
which may be withheld in such Investor’s sole discretion. If the Company believes public disclosure of an Investor’s or its
Affiliates’ relationship, agreements or arrangements with the Company is required by law, the Company shall at a reasonable time
before making any such disclosure (including, without limitation, filing any document or material with the SEC or any other regulatory
authority, which contains a reference to such Investor or its Affiliates), consult with such Investor regarding such disclosure, permit
such Investors to review such disclosure not less than ten (10) business days prior to its proposed disclosure (unless the Company
is legally obligated to make such disclosure on fewer than ten (10) business days’ notice, in which case the Company shall
give such Investor as much time to review such disclosure as is reasonably practicable, but in any event not less than two (2) business
days), revise such disclosure as reasonably requested by such Investor, and if requested by such Investor, seek confidential treatment
for any portion of any agreements or documents intended to be filed with the SEC or other regulatory authority as may be reasonably requested
by such Investor.


 


5.10            Acknowledgment.
The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans
and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly
or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing
or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the
Company.


 


5.11            FCPA.
The Company covenants that it shall not (and shall not permit any of its subsidiaries or Affiliates or any of its or their respective
directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment
to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such
term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation
of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it
shall (and shall cause each of its subsidiaries and Affiliates to) cease all of its or their respective activities, as well as remediate
any actions taken by the Company, its subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees,
independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery
or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) maintain
systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance
with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to
provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall
promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The Company
shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future,
to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence
or formed in the future, to comply in all material respects with all applicable laws.


 



    	 	 24	 



     


    

 


5.12             Real
Property Holding Corporation. Promptly following (and in any event within ten (10) days after receipt of) written request by
an Investor, the Company shall provide such Investor with a written statement informing such Investor whether such Investor’s interest
in the Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements
of Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely notice to the
Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any
successor regulation, that such statement has been made.


 


5.13             Termination
of Covenants. The covenants set forth in this Section 5, except for Sections 5.6, 5.7 and 5.9, shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon
a Deemed Liquidation Event (other than a sale of all or substantially all of the Company’s assets), whichever event occurs first.


 


6.            Miscellaneous.


 


6.1               Successors
and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee
of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for
the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer,
holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations,
and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer,
furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights
are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject
to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining
the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder
of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder
or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further
that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer,
establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement.
The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees
of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or
their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement,
except as expressly provided herein.


 






    	 	 25	 



     


    

 


6.2            Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to any conflicts of laws principles
that would require the application of laws of any other jurisdiction.


 


6.3            Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic
signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.


 


6.4            Titles
and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.


 


6.5            Notices.


 


(a)            All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon
the earlier of actual receipt or: (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail
or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, provided that in either case it is followed promptly by a confirming copy of the notice given via another authorized
means for that recipient, (iii) five (5) days after having been sent to a U.S. address by registered or certified mail, return
receipt requested, postage prepaid, addressed to the party to be notified at such party’s address as set forth on the signature
page or Schedule A or Schedule B hereto, or as subsequently modified by written notice, and if to the Company, (iv) two
(2) business days after deposit with a nationally recognized overnight courier, freight prepaid for delivery to a U.S. address, specifying
next business day delivery, with written verification of receipt, or (v) three (3) business days after deposit with an internationally
recognized expedited delivery services company, freight prepaid for delivery to a non-U.S. address, specifying next available business
day delivery, with written verification of receipt; provided, however, that notice and other communications given or made to Roche Finance
Ltd shall only be provided using the methods set forth in clauses (i), (ii) and (v) above. In addition to the above, if notice
is given to the Company, a copy (which shall not constitute notice) shall also be sent to Goodwin Procter LLP, 100 Northern Avenue, Boston,
MA 02210, Attention: Arthur McGivern, Fax: (617) 801-8626, E-mail: AMcGivern@goodwinlaw.com.


 


(b)            Consent
to Electronic Notice. Each Investor and Licensor Stockholder consents to the delivery of any stockholder notice pursuant to the Delaware
General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant
to Section 232 of the DGCL (or any successor thereto) at the electronic mail address set forth below such Investor’s or Licensor
Stockholder’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company.
Each Investor and Licensor Stockholder agrees to promptly notify the Company of any change in such stockholder’s electronic mail
address, and that failure to do so shall not affect the foregoing.


 






    	 	 26	 



     


    

 


6.6            Amendments
and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may
be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of
the Company and the Requisite Majority; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and
the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall
be deemed to be a waiver). Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the
observance of any term hereof may not be waived with respect to any Rights Stockholder without the written consent of such Rights Stockholder,
unless such amendment, modification, termination, or waiver applies to all Rights Stockholders in the same fashion (it being agreed that
a waiver of the provisions of Section 4 with respect to a particular transaction will be deemed to apply to all Rights Stockholders
in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Rights Stockholders may nonetheless, by
agreement with the Company, purchase securities in such transaction; provided that
Section 4.1(e) may not be waived in connection therewith with respect to any Waived Investor without the written
consent of such Waived Investor), (b) Section 3.3(a) and this Section 6.6(b) shall not be amended,
modified, terminated or waived without the written consent of 5AM Ventures, (c) Section 3.3(b) and this Section 6.6(b) shall
not be amended, modified, terminated or waived without the written consent of MRL Ventures, (d) Sections 3.3(c) and
this Section 6.6(b) shall not be amended, modified, terminated, or waived without the written consent of each of 667,
L.P. and Baker Brothers Life Sciences, L.P., (e) Section 3.3(d) and this Section 6.6(b) shall
not be amended, modified, terminated or waived without the written consent of Greenspring Associates, and (f) Sections 2.11,
3.1, 3.2, 3.4, 3.5 and 4 shall not be amended, modified, terminated or waived in a manner adverse
to the rights of the Wellington Investor without the written consent of the Wellington Investor. Notwithstanding the foregoing, Schedule
A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the
terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after
the date of this Agreement without the consent of the other parties to add information regarding any additional Investor or Licensor
Stockholder who becomes a party to this Agreement in accordance with Section 6.9. The Company shall give prompt notice of
any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment,
modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance with this Section 6.6
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to
any term, condition, or provision of this Agreement, in any one (1) or more instances, shall be deemed to be or construed as a further
or continuing waiver of any such term, condition, or provision.


 


6.7            Severability.
In case any one (1) or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.


 


6.8            Aggregation
of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining
the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any
manner they deem appropriate.


 



    	 	 27	 



     


    




 


6.9         Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Series B
Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series B
Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors
or Licensor Stockholders shall be required for such joinder to this Agreement by such additional Investor, so long as such additional
Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.


 


6.10       Entire
Agreement. This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement among the
parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing
between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be amended and restated
and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect.


 


6.11       Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of the State
of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action
or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding
arising out of or based upon this Agreement except in the state courts of the State of Delaware or the United States District Court for
the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such
suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property
is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue
of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.


 


WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES
ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS,
THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS
BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY
FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.


 






    	 	 28	 



     


    

 


6.12            Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.


 


[Remainder of Page Intentionally Left Blank]


 



    	 	 29	 



     


    




 


IN
WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above.


 


	 	ENTRADA THERAPEUTICS, INC.
	 	 
	 	By:	 /s/ Dipal Doshi
	 	Name:	 Dipal Doshi
	 	Title: 	President and CEO